Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
about
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular riskManagement of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
P2860
Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inhaled Long-Acting β2-Agonist ...... ents in COPD: A Meta-Analysis.
@ast
Inhaled Long-Acting β2-Agonist ...... ents in COPD: A Meta-Analysis.
@en
type
label
Inhaled Long-Acting β2-Agonist ...... ents in COPD: A Meta-Analysis.
@ast
Inhaled Long-Acting β2-Agonist ...... ents in COPD: A Meta-Analysis.
@en
prefLabel
Inhaled Long-Acting β2-Agonist ...... ents in COPD: A Meta-Analysis.
@ast
Inhaled Long-Acting β2-Agonist ...... ents in COPD: A Meta-Analysis.
@en
P2860
P1433
P1476
Inhaled Long-Acting β2-Agonist ...... ents in COPD: A Meta-Analysis.
@en
P2093
P2860
P304
P356
10.1371/JOURNAL.PONE.0137904
P407
P50
P577
2015-09-17T00:00:00Z